Efficacy and safety of high-dose chemotherapy as the first or subsequent salvage treatment line in patients with relapsed or refractory germ cell cancer: an international multicentric analysis
Details
Publication Year 2024-05,Volume 9,Issue #5,Page 103449
Journal Title
ESMO Open
Publication Type
Research article
Abstract
BACKGROUND: In relapsed or refractory (RR) metastatic germ cell cancer (GCC), high-dose (HD) chemotherapy (CTX) plus autologous stem cell transplantation is considered the standard of care. Limited data exist regarding the efficacy of HD-CTX following conventionally dosed salvage regimens (CDRs). This analysis explores and contrasts the efficacy of HD-CTX as the first or subsequent salvage regimen. PATIENTS AND METHODS: Data were retrospectively collected to explore the efficacy of HD-CTX administered as the first (group A) or subsequent salvage CTX (group B) after a CDR. The primary endpoint was OS from the time of HD-CTX. Associations of survival, overall response rate (ORR), and toxicity with clinical characteristics were explored using stratified Kaplan-Meier and Cox regression models. RESULTS: Overall, 283 patients with GCC were included from 11 international centers, with 159 patients (56%) in group A and 124 patients (44%) in group B. The first salvage treatment was administered between 1998 and 2022, with a median follow-up of 27.0 [standard deviation (SD) 46.2] months for group A and 17.0 (SD 48.5) months for group B. The median OS from HD-CTX treatment initiation was not reached in group A, compared with 25 months in group B (P = 0.00027), associated with 2- and 5-year OS rates of 74% and 63% (group A) versus 53% and 37% (group B), respectively. When administered as the first salvage treatment, HD-CTX was associated with a higher ORR (79% versus 60%; P = 0.013) and lower nonhematologic grade ≥3 toxicity rate (78% versus 97%; P < 0.001). Concerning risk factor analysis for the total cohort, the International Prognostic Factors Study Group score was the only independent predictor of OS in multivariable analysis (P = 0.006). CONCLUSIONS: When administered as the initial salvage treatment or after CDR, HD-CTX exhibits curative potential for patients with RR GCC. The efficacy and safety outcomes were more favorable when HD-CTX was conducted as the first salvage treatment line.
Publisher
Elsevier
Keywords
Humans; *Salvage Therapy/methods; Male; *Neoplasms, Germ Cell and Embryonal/drug therapy; Retrospective Studies; Adult; Middle Aged; Neoplasm Recurrence, Local/drug therapy; Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects; Young Adult; Treatment Outcome; Female; conventional-dose salvage regimens; high-dose chemotherapy; refractory germ cell tumor; relapse; salvage chemotherapy
Department(s)
Medical Oncology
Open Access at Publisher's Site
https://doi.org/10.1016/j.esmoop.2024.103449
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-07-18 03:28:03
Last Modified: 2024-07-18 03:32:48

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙